ATE468108T1 - Immunogene liposomzusammensetzungen - Google Patents

Immunogene liposomzusammensetzungen

Info

Publication number
ATE468108T1
ATE468108T1 AT99969329T AT99969329T ATE468108T1 AT E468108 T1 ATE468108 T1 AT E468108T1 AT 99969329 T AT99969329 T AT 99969329T AT 99969329 T AT99969329 T AT 99969329T AT E468108 T1 ATE468108 T1 AT E468108T1
Authority
AT
Austria
Prior art keywords
liposome compositions
immunogenic liposome
immunogenic
compositions
liposome
Prior art date
Application number
AT99969329T
Other languages
English (en)
Inventor
Gary Fujii
Donald CRAMER
William Ernst
Jill Adler-Moore
L Perry
Original Assignee
Molecular Express Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26798150&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE468108(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Molecular Express Inc filed Critical Molecular Express Inc
Application granted granted Critical
Publication of ATE468108T1 publication Critical patent/ATE468108T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT99969329T 1998-09-22 1999-09-22 Immunogene liposomzusammensetzungen ATE468108T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10135198P 1998-09-22 1998-09-22
US40072399A 1999-09-21 1999-09-21
PCT/US1999/020880 WO2000016746A2 (en) 1998-09-22 1999-09-22 Immunogenic liposome compositions

Publications (1)

Publication Number Publication Date
ATE468108T1 true ATE468108T1 (de) 2010-06-15

Family

ID=26798150

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99969329T ATE468108T1 (de) 1998-09-22 1999-09-22 Immunogene liposomzusammensetzungen

Country Status (30)

Country Link
EP (1) EP1115382B1 (de)
JP (1) JP2002526436A (de)
KR (1) KR100592825B1 (de)
CN (1) CN1555254A (de)
AP (1) AP2010A (de)
AT (1) ATE468108T1 (de)
AU (1) AU766772B2 (de)
BG (1) BG65675B1 (de)
BR (1) BR9914004A (de)
CA (1) CA2344173C (de)
CY (1) CY1110718T1 (de)
CZ (1) CZ20011013A3 (de)
DE (1) DE69942393D1 (de)
DK (1) DK1115382T3 (de)
EA (1) EA004797B1 (de)
EE (1) EE200100168A (de)
ES (1) ES2345695T3 (de)
GE (1) GEP20053444B (de)
HU (1) HUP0105391A3 (de)
ID (1) ID29082A (de)
IL (2) IL141675A0 (de)
MX (1) MXPA01002973A (de)
NO (1) NO330685B1 (de)
NZ (2) NZ528055A (de)
OA (1) OA11657A (de)
PL (1) PL206260B1 (de)
SK (1) SK287670B6 (de)
UA (1) UA75327C2 (de)
WO (1) WO2000016746A2 (de)
ZA (1) ZA200101829B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006110831A2 (en) * 2005-04-12 2006-10-19 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
WO2010140377A1 (ja) 2009-06-04 2010-12-09 独立行政法人産業技術総合研究所 マイコプラズマ感染症用ワクチン
JP2014518620A (ja) * 2011-04-26 2014-08-07 モレキュラー エクスプレス,インコーポレイテッド リポソーム製剤
WO2015048635A1 (en) 2013-09-27 2015-04-02 Duke University Mper-liposome conjugates and uses thereof
JP2020515629A (ja) 2017-04-04 2020-05-28 アヴィディア テクノロジーズ, インコーポレイテッド 免疫応答を誘導するためのペプチドベースのワクチン、それらの製造方法および使用
KR102901149B1 (ko) * 2022-09-05 2025-12-17 주식회사 차백신연구소 에멀전 제형의 면역증강제 조성물 및 이의 제조 방법
AU2023367780A1 (en) 2022-10-25 2025-03-27 Barinthus Biotherapeutics North America, Inc. Self-assembling nanoparticles

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8405493D0 (sv) * 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US5374548A (en) * 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
SE462375B (sv) * 1985-10-15 1990-06-18 Morgaardshammar Ab Centro Traadblock
US4861597A (en) * 1986-05-20 1989-08-29 Wako Pure Chemical Industries, Ltd. Novel functionallized liposomes and a process for production thereof
FR2754543B1 (fr) * 1996-10-11 1998-12-31 Pasteur Institut Souche de bordetella deficiente dans la production de toxine et exprimant une proteine hydride, liposomes comprenant de la fha et leurs utilisations comme vaccins, et utilisation de la fha pour stimuler les reponses immunitaires

Also Published As

Publication number Publication date
JP2002526436A (ja) 2002-08-20
EA004797B1 (ru) 2004-08-26
NO330685B1 (no) 2011-06-06
EA200100269A1 (ru) 2001-12-24
WO2000016746A8 (en) 2000-08-10
CY1110718T1 (el) 2015-06-10
NO20011406D0 (no) 2001-03-20
HUP0105391A2 (hu) 2002-05-29
UA75327C2 (en) 2006-04-17
CN1555254A (zh) 2004-12-15
WO2000016746A2 (en) 2000-03-30
NZ510442A (en) 2003-10-31
MXPA01002973A (es) 2003-03-27
AP2010A (en) 2009-06-29
GEP20053444B (en) 2005-02-25
CA2344173A1 (en) 2000-03-30
EE200100168A (et) 2002-06-17
ES2345695T3 (es) 2010-09-29
WO2000016746A9 (en) 2000-09-21
BG65675B1 (bg) 2009-06-30
PL348604A1 (en) 2002-06-03
IL141675A (en) 2007-06-17
NO20011406L (no) 2001-04-24
AU6035199A (en) 2000-04-10
DK1115382T3 (da) 2010-09-06
SK287670B6 (sk) 2011-05-06
KR100592825B1 (ko) 2006-06-23
AP2001002096A0 (en) 2001-03-31
NZ528055A (en) 2005-01-28
KR20010075261A (ko) 2001-08-09
IL141675A0 (en) 2002-03-10
ZA200101829B (en) 2002-06-05
SK3222001A3 (en) 2001-09-11
WO2000016746A3 (en) 2000-11-23
OA11657A (en) 2004-12-08
EP1115382A2 (de) 2001-07-18
DE69942393D1 (de) 2010-07-01
BR9914004A (pt) 2001-07-24
HUP0105391A3 (en) 2006-02-28
BG105372A (en) 2001-10-31
HK1039064A1 (en) 2002-04-12
ID29082A (id) 2001-07-26
CA2344173C (en) 2010-02-23
PL206260B1 (pl) 2010-07-30
AU766772B2 (en) 2003-10-23
EP1115382B1 (de) 2010-05-19
CZ20011013A3 (cs) 2002-03-13

Similar Documents

Publication Publication Date Title
ATE339223T1 (de) Kombinierte impfstoffzusammensetzungen
NO20004758L (no) Vaksinesammensetning
FI981011L (fi) Uudet koostumukset
ID26926A (id) Komposisi shampo pembentuk mode
ID26549A (id) Komposisi-komposisi epotilon
ATE367793T1 (de) Schweisshemmende zusammensetzungen
DE59905792D1 (de) Leistungsschalter
NO20021116D0 (no) Ny sammensetning
ATE469550T1 (de) Antiparasitäre zusammensetzungen
DE69911270D1 (de) Schutzschalter
NO20021115D0 (no) Ny sammensetning
DE69927758D1 (de) Imidosilan-Zusammensetzungen
DE59913448D1 (de) Leistungsschalter
DK0974399T3 (da) Rotordyse
ID27889A (id) Komposisi-komposisi kopolimer polisiklik
PT1124567E (pt) Composicoes tamponadas para dialise
DE69931222D1 (de) Schutzschalter
DE69930795D1 (de) Schutzschalter
DE60040058D1 (de) Schutzschalter
DE69942393D1 (de) Immunogene liposomzusammensetzungen
FIU990494U0 (fi) Uusi koostumus
NO20005483D0 (no) Ny sammensetning
IS5877A (is) Ný efnablanda
DE69901091D1 (de) Schutzschalter
IS5879A (is) Ný efnablanda

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1115382

Country of ref document: EP